Inhaled 5-methoxy-N,N-dimethyltryptamine
Supportive context associated with positive acute and enduring effects
Bibliographic Data
| ID | 4695897 |
|---|---|
| Authors | Nathan D Sepeda (Johns Hopkins University, corresponding author), John M Clifton, John Clifton (Johns Hopkins Medicine), Laura Y Doyle (Johns Hopkins University), Rafael Lancelotta, Rafaelle L Lancelotta (0000-0002-7789-3463, University of Wyoming), Roland R Griffiths (0000-0001-5185-7854, Johns Hopkins Medicine), A K Davis (0000-0003-4770-8893, The Ohio State University) |
| Year | 2020 |
| Volume | 4 |
| Issue | 2 |
| Pages | 114-122 |
| Publication date | 2020-06-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Journal of Psychedelic Studies (JOURNAL) |
| Journal identifiers | ISSN: 2559-9283 • E-ISSN: 2559-9283 |
| Publisher | Akademiai Kiado Zrt (PUBLISHER) |
| DOI | 10.1556/2054.2019.033 |
| OpenAlex | W2998604208 |
| Language | EN |
| Citations received | 4 |
| References cited | 33 |
Background and aims 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a potent, short-acting psychedelic that produces strong hallucinogenic effects. The association between the context (i.e., set and setting) of 5-MeO-DMT use and the acute and enduring effects of the substance is unknown. Therefore, this study examined these associations using secondary data from two cross-sectional survey studies. Methods The acute and enduring effects of inhaled synthetic 5-MeO-DMT were compared between individuals who used 5-MeO-DMT in a non-structured context (NSC; n = 216, female = 10%, Mage = 35.5, SD = 11.8) and those who used in a structured context (SC; n = 362, female = 45%, Mage = 47.7, SD = 13.3). Questionnaires were administered online and responses were anonymized for privacy purposes. Respondents were asked to retrospectively rate their first experience with synthesized 5-MeO-DMT on measures of mystical experience, challenging experience, and enduring effects. Results Both groups endorsed high ratings on the Mystical Experience Questionnaire; however, mean scores were significantly higher in the SC group compared to the NSC group. Similarly, the proportion of respondents who had a complete mystical experience was significantly larger in the SC group (83%) compared to the NSC group (54%). Ratings of enduring effects (i.e., meaningfulness, spirituality, and well-being) were also significantly higher, and the intensity of challenging experiences was significantly lower, in the SC group compared to the NSC group. Conclusions 5-MeO-DMT appears to occasion mystical-type experiences with enduring positive effects, which are more intense when 5-MeO-DMT is administered in a safe and supportive context. Future prospective experimental studies should examine the effects of 5-MeO-DMT and its interactive relationship with supportive contextual factors
Alternative medicine · Mysticism · Spirituality · Theology · Chemical synthesis and alkaloids · Clinical Psychology · Forensic Toxicology and Drug Analysis · Medicine · Psychedelics and Drug Studies · Psychology
Altered States of Consciousness During Ceremonial San Pedro Use
Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures
A Scoping Review of Research in Naturalistic Studies with Psychedelics
Predictors and potentiators of psychedelic-occasioned mystical experiences
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
Survey study of challenging experiences after ingesting psilocybin mushrooms
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Human hallucinogen research
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
Survey of subjective "God encounter experiences"
The Challenging Experience Questionnaire
Psilocybin with psychological support for treatment-resistant depression
Psychedelics
Psilocybin occasioned mystical-type experiences
Über Die Synthese Des Bufotenin-Methyl-Äthers (5-Methoxy-N-Dimethyl-Tryptamin) Und Bufotenins (Synthesen in Der Indol-Gruppe. Xv)
Implications of LSD and experimental mysticism
Bufo alvarius
Pharmepéna-Psychonautics
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users
Bufo Toads and Bufotenine
Factor Analysis of the Mystical Experience Questionnaire
| Unique citing works | 4 |
|---|---|
| Citations per year | 1 |
| Citation span | 2022 - 2025 (4) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 4 |